About: Prevalence of comorbidities and their association with mortality in patients with COVID‐19: A Systematic Review and Meta‐analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence of comorbidities and their association with mortality in patients with COVID‐19: A Systematic Review and Meta‐analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Prevalence of comorbidities and their association with mortality in patients with COVID‐19: A Systematic Review and Meta‐analysis
Creator	Davies, Melanie Singh, Akriti Singh, Awadhesh Singh, Ritu Chudasama, Yogini Coles, Briana Gillies, Clare Khunti, Kamlesh Seidu, Sam Zaccardi, Francesco
source	Medline; PMC; WHO
abstract	AIMS: COVID‐19 is a global pandemic that as of the 4th May has registered over 3 585 711 confirmed cases and 248 780 deaths. This review aims to estimate the prevalence of both cardiometabolic and other co‐morbidities in patients with COVID‐19 infection, and to estimate the increased risk of severity and mortality in people with co‐morbidities. MATERIALS AND METHODS: Medline, Scopus and the World Health Organisation (WHO) website for Global research on COVID‐19 were searched from January 2019 up to April 23, 2020. Study inclusion was restricted to English language publications, original articles that reported prevalence of co‐morbidities in individuals with COVID‐19 disease, and case‐series >10 patients. 18 studies were selected for inclusion. Data were analysed using random effects meta‐analysis models. RESULTS: Eighteen studies with a total of 14 558 individuals were identified. The pooled prevalence for co‐morbidities in patients with COVID‐19 disease was 22.9% (95% CI: 15.8 to 29.9) for hypertension; 11.5% (9.7 to 13.4) for diabetes; and 9.7% (6.8 to 12.6) for cardiovascular disease (CVD). For chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular disease, and cancer, the pooled prevalences were all less than 4%. With the exception of cerebrovascular disease, all other co‐morbidities had a significantly increased risk for having severe COVID‐19. In addition, the risk of mortality was significantly increased in individuals with CVD, COPD, CKD, cerebrovascular disease, and cancer. CONCLUSIONS: In individuals with COVID‐19, the presence of co‐morbidities (both cardiometabolic and other) is associated with a higher risk of severe COVID‐19 and mortality. These findings have important implications for the public health with regards to risk stratification and future planning. This article is protected by copyright. All rights reserved.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1111/dom.14124
bibo:pmid	32573903
has license	no-cc
sha1sum (hex)	f1b49404a498d887738d2d309e8f53894b6b24b6
schema:url	https://doi.org/10.1111/dom.14124
resource representing a document's title	Prevalence of comorbidities and their association with mortality in patients with COVID‐19: A Systematic Review and Meta‐analysis
has PubMed Central identifier	PMC7361304
has PubMed identifier	32573903
schema:publication	Diabetes Obes Metab
resource representing a document's body	covid:f1b49404a498d887738d2d309e8f53894b6b24b6#body_text
is schema:about of	named entity 'infection' named entity 'comorbidities' named entity 'Systematic' named entity 'CO-MORBIDITIES' named entity 'REVIEW' named entity 'This' named entity 'patients' named entity 'COVID-19 infection' named entity 'Meta-analysis' named entity 'COVID' named entity 'COVID-19' named entity 'comorbidities' named entity 'Meta-Analyses' named entity 'English language' named entity 'cardiovascular disease' named entity 'CKD' named entity 'meta-analyses' named entity 'ethnicity' named entity 'comorbidities' named entity 'relative risk' named entity 'comorbidities' named entity 'case reports' named entity 'meta-analyses' named entity 'co-morbidities' named entity 'meta-analyses' named entity 'China' named entity 'COVID-19' named entity 'dependent variable' named entity '5.4' named entity 'cerebrovascular disease' named entity 'cough' named entity 'COVID' named entity 'COVID-19' named entity 'meta-analysis' named entity 'co-morbidities' named entity 'comorbidities' named entity 'risk factors' named entity 'COVID' named entity 'BMI' named entity '5.2' named entity 'systematic reviews' named entity 'type 1 error' named entity 'Stata' named entity 'co-morbidities' named entity 'respiratory rate' named entity 'morbidities' named entity 'cerebrovascular disease' named entity 'China' named entity 'co-morbidities' named entity 'meta-analyses' named entity 'meta-analyses' named entity 'COVID' named entity 'effect size' named entity 'general population' named entity 'Wuhan' named entity 'COVID' named entity 'in-patients' named entity 'obesity' named entity 'cerebrovascular disease' named entity 'CKD' named entity 'COVID' named entity 'asymptomatic' named entity 'health care workers' named entity 'COVID' named entity 'virus' named entity 'COVID' named entity 'meta-analysis' named entity 'heterogeneity' named entity 'risk stratification' named entity 'cerebrovascular disease' named entity 'COPD' named entity 'cardiovascular'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software